Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Baxter
Fish and Richardson
UBS
Queensland Health
McKinsey
Harvard Business School
Cantor Fitzgerald

Generated: April 19, 2018

DrugPatentWatch Database Preview

CANCIDAS Drug Profile

« Back to Dashboard

When do Cancidas patents expire, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
Drug patent expirations by year for CANCIDAS
Pharmacology for CANCIDAS
Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

US Patents and Regulatory Information for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-002 Jan 26, 2001 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CANCIDAS
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe For Injection 50 mg/vial and 70 mg/vial ➤ Subscribe 2009-06-26

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Dow
Baxter
Citi
UBS
Fuji
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.